Functional rejuvenation of endothelial cell aging by transient reprogramming
By
Katrin Kalies
Kai Knoepp
Laura Hehl
Simon Guerlach
Laura Sandiano
Andreas Simm
Jochen Dutzmann
Daniel Sedding
June 26, 2026
Clinical Scorecard: Reversing Aging Effects in Endothelial Cells Through Temporary Reprogramming Techniques
At a Glance
Category Detail
Condition Endothelial Dysfunction Key Mechanisms Cellular senescence, endothelial cell reprogramming, angiogenic capacity restoration Target Population Aging individuals with cardiovascular diseases Care Setting Research and clinical trials
Key Highlights
Endothelial dysfunction is a major contributor to cardiovascular diseases. Temporary reprogramming using FDA-approved compounds can rejuvenate senescent endothelial cells. The pharmacological cocktail includes valproic acid, lithium carbonate, and galunisertib. Guideline-Based Recommendations
Diagnosis
Assess endothelial function and cellular senescence in patients with cardiovascular diseases. Management
Consider pharmacological reprogramming strategies for improving endothelial function. Monitoring & Follow-up
Monitor vascular health and endothelial function post-treatment. Risks
Potential genomic instability associated with viral reprogramming techniques. Patient & Prescribing Data
Patients with age-related endothelial dysfunction
Utilization of a pharmacological cocktail for temporary reprogramming shows promise in restoring endothelial function.
Clinical Best Practices
Incorporate assessment of endothelial function in routine cardiovascular evaluations. Explore safe pharmacological options for endothelial rejuvenation in clinical settings. Related Resources & Content
